Tessa Therapeutics: Scientific session at SDCT-REMEDIS Cell Therapy Conference 2022

KUALA LUMPUR, June 14 (Bernama) -- Tessa Therapeutics Ltd (Tessa), a clinical-stage cell therapy company, announced it will host a scientific session during the SDCT-REMEDIS Cell Therapy Conference 2022 being held virtually from June 23-24, 2022.

Tessa’s scientific session will focus on CD30 CAR-T targeting of CD30+ lymphomas and will feature a presentation from Dr Ivan Horak, Chief Medical Officer and Chief Scientific Officer of Tessa Therapeutics.

The discussion will be moderated by Dr Han Chong Toh, Deputy Medical Director, National Cancer Centre Singapore (NCCS), Associate Professor, Cancer & Stem Cell Biology Program and SingHealth-Duke Global Health Institute, Duke-NUS, and Head of Cancer Immunotherapy at the SingHealth Duke-NUS Cell Therapy Centre.

“We are very pleased to host a scientific session at the SDCT-REMEDIS Cell Therapy Conference 2022 as it provides an opportunity to educate researchers on opportunities to treat CD30-positive lymphomas via CAR-T and the unique approaches being advanced by Tessa,” said Dr Horak in a statement.

“We look forward to progressing clinical programmes investigating our autologous (TT11) and allogenic (TT11X) CAR-T technologies during 2022, with several development milestones expected throughout the year.”

Tessa is currently advancing two clinical programmes leveraging distinct CD30 CAR-T technologies for the treatment of CD30+ lymphomas.

Tessa’s lead clinical programme – TT11 – is an autologous CD30 targeting CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma.

Additionally, Tessa is developing an allogenic ‘off-the-shelf’ CD30-CAR EBVST cell therapy – TT11X – targeting relapsed or refractory CD30-positive lymphomas. Data demonstrating the safety and efficacy of both programmes was previously presented at the 2021 ASH Annual Meeting.

Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumours.

More details at www.tessacell.com.

-- BERNAMA